As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Heron Therapeutics, Inc. The largest reported stake is Rubric Capital Management LP's, at 15.9%. 8 filings are on record since August 12, 2025 (Schedule 13D/A, October 17, 2025).
Sell to companies like Heron Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Adage Capital Management, L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
- · Holder: Clearline Capital LP · Percent: 6.7% · SCHEDULE 13G/A
- · Holder: The Vanguard Group · Percent: 5.35% · SCHEDULE 13G
- · Holder: Clearline Capital LP · Percent: 5.3% · SCHEDULE 13G
Heron Therapeutics, Inc. has 8 Schedule 13D or 13G filings on record since 2025-08-12. 2 holders' latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Rubric Capital Management LP | 15.9% | 30,046,828 | SCHEDULE 13D/A, 2025-10-17 | 2025-10-15 |
| Clearline Capital LP | 6.7% | 12,235,239 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
| Adage Capital Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-05-13 | 2026-03-31 |
Holding shares or following this stake? See who's behind Heron Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Heron Therapeutics, Inc. and the records around it.
Heron Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Clearline Capital LP also filed stake reports on 2 other companies: Xperi Inc. (Aug 2026), MAGNACHIP SEMICONDUCTOR Corp (Feb 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
- Adage Capital Management, L.P. also filed stake reports on 136 other companies: ACP Holdings Acquisition Corp. (Aug 2026), AmperCap Acquisition Company (Aug 2026), Aura Biosciences, Inc. (Aug 2026)
Watch Heron Therapeutics, Inc.
Get an email when Heron Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Heron Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Heron Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Heron Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Rubric Capital Management LP
On October 15, 2025, the Issuer filed a Current Report on Form 8-K with the SEC disclosing that it obtained Stockholder Approval, as a result of which, the 94,610 shares of Preferred Stock beneficially owned by the Reporting Persons automatically converted, without any action on the part of the holders thereof, into 946,100 Shares. Additionally, as previously disclosed, on August 8, 2025, a certain Rubric Fund entered into the Note Purchase Agreement with the Issuer, pursuant to which the Issuer issued and sold to such Rubric Fund $35,000,000 aggregate principal amount of Notes for an aggregate purchase price of $33,250,000. The Convertible Note Issuance provided for the issuance of Notes with (i) a maturity date of March 1, 2031, (ii) a 5% original issuance discount, (iii) 5% per annum interest payable in cash, and (iv) at the election of the Issuer, 7% per annum interest payable in kind for the first twelve months. As a result of the Stockholder Approval, after December 31, 2025, the Notes are convertible at the election of the holders thereof, at an initial conversion rate of 555.5556 Shares per $1,000 principal amount of Notes, subject to adjustments as provided in the Note Purchase Agreement. Conversions of the Notes can be settled, at the Issuer's election, in cash, Shares or in a combination thereof. If all or any portion of any conversion is to be settled in cash, the amount of cash that the Issuer will be required to deliver with respect to such conversion in …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-10-17; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Rubric Capital Management LP | 17.5% | SCHEDULE 13D/A |
| 2025-10-17 | Rubric Capital Management LP | 15.9% | SCHEDULE 13D/A |
| 2025-10-30 | The Vanguard Group | 4.61% | SCHEDULE 13G/A |
| 2025-11-26 | Clearline Capital LP | 5.3% | SCHEDULE 13G |
| 2026-01-30 | The Vanguard Group | 5.35% | SCHEDULE 13G |
| 2026-02-17 | Clearline Capital LP | 6.7% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-13 | Adage Capital Management, L.P. | 0% | SCHEDULE 13G/A |
Questions about who owns Heron Therapeutics, Inc.
Who owns Heron Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Heron Therapeutics, Inc.: Rubric Capital Management LP (15.9%, Schedule 13D/A, filed 2025-10-17) and Clearline Capital LP (6.7%, Schedule 13G/A, filed 2026-02-17).
Who are the largest shareholders of Heron Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Heron Therapeutics, Inc. on this page are Rubric Capital Management LP (15.9%) and Clearline Capital LP (6.7%).
When did Rubric Capital Management LP buy into Heron Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Rubric Capital Management LP on this page is the Schedule 13D/A, filed 2025-08-12, reporting 17.5%; its latest, Schedule 13D/A filed 2025-10-17, reports 15.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Heron Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 6, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Heron Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.